Cargando…

European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad

BACKGROUND: As hospitals have a high prevalence of multidrug-resistant organisms (MDRO), hospitalization abroad indicates for travellers an increased risk of acquiring MDRO—and carrying the strains home. Antimicrobial resistance (AMR) rates are highest in the (sub)tropics, whereas Europe is consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Kajova, Mikael, Khawaja, Tamim, Kantele, Anu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282090/
https://www.ncbi.nlm.nih.gov/pubmed/35234907
http://dx.doi.org/10.1093/jtm/taac022
_version_ 1784747031891279872
author Kajova, Mikael
Khawaja, Tamim
Kantele, Anu
author_facet Kajova, Mikael
Khawaja, Tamim
Kantele, Anu
author_sort Kajova, Mikael
collection PubMed
description BACKGROUND: As hospitals have a high prevalence of multidrug-resistant organisms (MDRO), hospitalization abroad indicates for travellers an increased risk of acquiring MDRO—and carrying the strains home. Antimicrobial resistance (AMR) rates are highest in the (sub)tropics, whereas Europe is considered a lower risk region. Since AMR prevalences vary within Europe, we aimed to gather country-specific data on the risks for hospitalized travellers. METHODS: At hospitals of the Helsinki and Uusimaa district in Finland, patients hospitalized abroad over the past 12 months are systematically screened for methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales (ESBL-PE), carbapenemase-producing bacteria and vancomycin-resistant Enterococcus spp. (VRE). Among patients screened 2010–19, we selected those hospitalized in Europe, recorded their MDRO findings, infections and mortality, and analysed MDRO-associated risk factors. RESULTS: Of the 1772 patients treated in 41 European countries, 16.6% (295) carried MDRO, 12.5% (221) ESBL-PE, 7.8% (138) solely ESBL-E. coli, 2.6% (46) MRSA, 2.2% (30) of those screened VRE and 2.2% (39) carbapenem-resistant Gram-negatives. Among those colonized, 9.8% (29) had symptomatic MDRO infections and 0.3% (one) died. Colonization was most frequently recorded for those treated in eastern and southern Europe, with Bulgaria, Cyprus and the Russian Federation scoring highest. MDRO colonization was associated with antibiotic treatment and showed a negative correlation with time from discharge to screening. CONCLUSIONS: After hospitalization in European countries, ESBL-PE carriage was relatively common (12.5%), while other MDROs proved less frequent (<5%). Antibiotic treatment and short time since hospitalization abroad increased the risk of MDRO colonization. Clear differences between countries and regions were revealed, with highest rates in the east and the south.
format Online
Article
Text
id pubmed-9282090
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92820902022-07-18 European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad Kajova, Mikael Khawaja, Tamim Kantele, Anu J Travel Med Original Article BACKGROUND: As hospitals have a high prevalence of multidrug-resistant organisms (MDRO), hospitalization abroad indicates for travellers an increased risk of acquiring MDRO—and carrying the strains home. Antimicrobial resistance (AMR) rates are highest in the (sub)tropics, whereas Europe is considered a lower risk region. Since AMR prevalences vary within Europe, we aimed to gather country-specific data on the risks for hospitalized travellers. METHODS: At hospitals of the Helsinki and Uusimaa district in Finland, patients hospitalized abroad over the past 12 months are systematically screened for methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales (ESBL-PE), carbapenemase-producing bacteria and vancomycin-resistant Enterococcus spp. (VRE). Among patients screened 2010–19, we selected those hospitalized in Europe, recorded their MDRO findings, infections and mortality, and analysed MDRO-associated risk factors. RESULTS: Of the 1772 patients treated in 41 European countries, 16.6% (295) carried MDRO, 12.5% (221) ESBL-PE, 7.8% (138) solely ESBL-E. coli, 2.6% (46) MRSA, 2.2% (30) of those screened VRE and 2.2% (39) carbapenem-resistant Gram-negatives. Among those colonized, 9.8% (29) had symptomatic MDRO infections and 0.3% (one) died. Colonization was most frequently recorded for those treated in eastern and southern Europe, with Bulgaria, Cyprus and the Russian Federation scoring highest. MDRO colonization was associated with antibiotic treatment and showed a negative correlation with time from discharge to screening. CONCLUSIONS: After hospitalization in European countries, ESBL-PE carriage was relatively common (12.5%), while other MDROs proved less frequent (<5%). Antibiotic treatment and short time since hospitalization abroad increased the risk of MDRO colonization. Clear differences between countries and regions were revealed, with highest rates in the east and the south. Oxford University Press 2022-03-02 /pmc/articles/PMC9282090/ /pubmed/35234907 http://dx.doi.org/10.1093/jtm/taac022 Text en © International Society of Travel Medicine 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kajova, Mikael
Khawaja, Tamim
Kantele, Anu
European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad
title European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad
title_full European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad
title_fullStr European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad
title_full_unstemmed European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad
title_short European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad
title_sort european hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in finland after hospitalization abroad
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282090/
https://www.ncbi.nlm.nih.gov/pubmed/35234907
http://dx.doi.org/10.1093/jtm/taac022
work_keys_str_mv AT kajovamikael europeanhospitalsassourceofmultidrugresistantbacteriaanalysisoftravellersscreenedinfinlandafterhospitalizationabroad
AT khawajatamim europeanhospitalsassourceofmultidrugresistantbacteriaanalysisoftravellersscreenedinfinlandafterhospitalizationabroad
AT kanteleanu europeanhospitalsassourceofmultidrugresistantbacteriaanalysisoftravellersscreenedinfinlandafterhospitalizationabroad